Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer.
The company seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients.
Merrimack currently has six oncology therapeutics in clinical development and three additional candidates in late stage preclinical development. Merrimack?s lead product candidate, MM-398, recently completed a Phase III trial in post-gemcitabine pancreatic cancer. Based on the results of this trial, Merrimack intends to file a New Drug Application for MM-398 in 2014.
MM-302 is another drug in development by Merrimack. This novel antibody-drug conjugated liposomal doxorubicin that targets and binds to HER2, a protein that when overexpressed can lead to the development and aggressive progression of breast cancer.?In December 2013, the reported encouraging trial results from an ongoing Phase 1 trial of MM-302 at SABCS, noting that patients treated with the nanoliposomal candidate showed?no cardiotoxicity related to MM-302, a side effect that has limited the use of anthracyclines, particularly in HER2-positive breast cancer.
In august 2014 the company ?initiated a new, global, open-label, randomized Phase II?trial of MM-302 in combination with trastuzumab (Herceptin?; Genetech/Roche) in patients with HER2-positive locally advanced or metastatic breast cancer.??This trial is ?trial designed with input from the U.S. Food and Drug Administration (FDA) to support a potential accelerated approval application of the trial drug.
One Kendall Square, Suite B7201
Cambridge, MA 02139